Ann: Imugene Presentation to Bell Potter Conference, page-35

I tried to warn you guys...

Another clinical trial update for CF33 with higher dosing regimens:




There have been 0 durable responses in the 9 patients treated between the 12th of January and 24th of April. These patients would have received greater doses of CF33 relative to the earlier patients, indicating efficacy is unrelated to dose. Stable disease and disease control rates are considered negative outcomes when there are standard of care drugs that a drug is competing against. Remember @reon1 you are valuing CF33 based on each cancer types global market where there are all the competitors that achieve consistent meaningful responses in patients.

CF33 forms the backbone for 3 of IMUs programs. Further failure to achieve objective clinical responses is going to cause these programs to come crashing down.

It is difficult to come to strong conlcusions without all the data, but I think there is enough to reasonably conclude CF33 will not recover from here. I think Azer-cel is the future of IMU. I haven't looked at it yet, but I will and I'll share my analysis when I do.